265 related articles for article (PubMed ID: 31866328)
1. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Niederman MS; Alder J; Bassetti M; Boateng F; Cao B; Corkery K; Dhand R; Kaye KS; Lawatscheck R; McLeroth P; Nicolau DP; Wang C; Wood GC; Wunderink RG; Chastre J
Lancet Infect Dis; 2020 Mar; 20(3):330-340. PubMed ID: 31866328
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
Kollef MH; Ricard JD; Roux D; Francois B; Ischaki E; Rozgonyi Z; Boulain T; Ivanyi Z; János G; Garot D; Koura F; Zakynthinos E; Dimopoulos G; Torres A; Danker W; Montgomery AB
Chest; 2017 Jun; 151(6):1239-1246. PubMed ID: 27890714
[TBL] [Abstract][Full Text] [Related]
5. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.
Niederman MS; Chastre J; Corkery K; Fink JB; Luyt CE; García MS
Intensive Care Med; 2012 Feb; 38(2):263-71. PubMed ID: 22147112
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
8. Aerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial.
Liu C; Zhang YT; Peng ZY; Zhou Q; Hu B; Zhou H; Li JG
Chin Med J (Engl); 2017 May; 130(10):1196-1201. PubMed ID: 28485320
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
[TBL] [Abstract][Full Text] [Related]
10. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
Montgomery AB; Vallance S; Abuan T; Tservistas M; Davies A
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):441-8. PubMed ID: 24383962
[TBL] [Abstract][Full Text] [Related]
13. Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
Hassan NA; Awdallah FF; Abbassi MM; Sabry NA
Crit Care Med; 2018 Jan; 46(1):45-52. PubMed ID: 28857848
[TBL] [Abstract][Full Text] [Related]
14. Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Ehrmann S; Barbier F; Demiselle J; Quenot JP; Herbrecht JE; Roux D; Lacherade JC; Landais M; Seguin P; Schnell D; Veinstein A; Gouin P; Lasocki S; Lu Q; Beduneau G; Ferrandiere M; Plantefève G; Dahyot-Fizelier C; Chebib N; Mercier E; Heuzé-Vourc'h N; Respaud R; Gregoire N; Garot D; Nay MA; Meziani F; Andreu P; Clere-Jehl R; Zucman N; Azaïs MA; Saint-Martin M; Gandonnière CS; Benzekri D; Merdji H; Tavernier E;
N Engl J Med; 2023 Nov; 389(22):2052-2062. PubMed ID: 37888914
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
17. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance.
Ghannam DE; Rodriguez GH; Raad II; Safdar A
Eur J Clin Microbiol Infect Dis; 2009 Mar; 28(3):253-9. PubMed ID: 18752007
[TBL] [Abstract][Full Text] [Related]
18. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
19. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
[TBL] [Abstract][Full Text] [Related]
20. Inhaled antibiotics for the treatment of pneumonia.
Schreiber MP; Shorr AF
Curr Opin Pulm Med; 2019 May; 25(3):289-293. PubMed ID: 30562188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
